Nilutamidum [Latin] en es it fr

Nilutamidum [Latin] Brand names, Nilutamidum [Latin] Analogs

Nilutamidum [Latin] Brand Names Mixture

  • No information avaliable

Nilutamidum [Latin] Chemical_Formula


Nilutamidum [Latin] RX_link

Nilutamidum [Latin] fda sheet

Nilutamidum [Latin] msds (material safety sheet)

Nilutamidum [Latin] Synthesis Reference

No information avaliable

Nilutamidum [Latin] Molecular Weight

317.221 g/mol

Nilutamidum [Latin] Melting Point

No information avaliable

Nilutamidum [Latin] H2O Solubility

No information avaliable

Nilutamidum [Latin] State


Nilutamidum [Latin] LogP


Nilutamidum [Latin] Dosage Forms


Nilutamidum [Latin] Indication

For use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D2)

Nilutamidum [Latin] Pharmacology

Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Nilutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.

Nilutamidum [Latin] Absorption

Rapidly and completely absorbed, yielding high and persistent plasma concentrations.

Nilutamidum [Latin] side effects and Toxicity

Symptoms of overdose include dizziness, general discomfort, headache, nausea, and vomiting.

Nilutamidum [Latin] Patient Information

Patients should be informed that NILANDRON tablets should be started on the day of, or on the day after, surgical castration. They should also be informed that they should not interrupt their dosing of NILANDRON or stop taking this medication without consulting their physician.
Because of the possibility of interstitial pneumonitis, patients should also be told to report immediately any dyspnea or aggravation of pre-existing dyspnea.

Because of the possibility of hepatitis, patients should be told to consult with their physician should nausea, vomiting, abdominal pain, or jaundice occur.
Because of the possibility of an intolerance to alcohol (facial flushes, malaise, hypotension) following ingestion of NILANDRON, it is recommended that intake of alcoholic beverages be avoided by patients who experience this reaction. This effect has been reported in about 5% of patients treated with NILANDRON.

In clinical trials, 13% to 57% of patients receiving NILANDRON reported a delay in adaptation to dark, ranging from seconds to a few minutes, when passing from a lighted area to a dark area. This effect sometimes does not abate as drug treatment is continued. Patients who experience this effect should be cautioned about driving at night or through tunnels. This effect can be alleviated by the wearing of tinted glasses.

Nilutamidum [Latin] Organisms Affected

Humans and other mammals